相关实验视频

Updated: Jul 17, 2025

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on ¹⁸F-AV-1451

Published on: April 18, 2025

阿尔茨海默病中与粉样蛋白相关的成像异常,用抗粉样蛋白β疗法治疗

Amit Agarwal¹, Vivek Gupta¹, Pavan Brahmbhatt¹

¹From the Departments of Radiology (A.A., V.G., P.B., A.D.) and Neuroradiology (P.V.), Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224; Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Mo (N.J.M.); and Department of Radiology, Mayo Clinic, Rochester, Minn (G.B.).

Radiographics : a review publication of the Radiological Society of North America, Inc

|August 31, 2023

概括

针对阿尔茨海默病 (AD) 的单克隆抗体免疫疗法减少了粉样质斑块,但可能导致粉样质相关的成像异常 (ARIA). 放射科医生必须识别和监测ARIA,包括 (ARIA-E) 和出血 (ARIA-H),以获得安全的治疗.

科学领域:

神经学神经学
免疫治疗是一种免疫疗法.
放射学放射学是一门学科.

背景情况:

阿尔茨海默病 (AD) 是全球痴呆的主要原因.
目前的AD治疗主要集中在症状管理上.
单克隆抗体 (MAB) 免疫疗法是一种针对粉样斑减少的新型治疗方法.

研究的目的:

讨论MABs在治疗AD中的作用.
扩展MAB治疗的并发症,特别是与粉样蛋白相关的成像异常 (ARIA).
描述ARIA的识别,分级和监测,以指导MAB治疗.

主要方法:

对阿尔茨海默病的MABs当前文献的综述.
ARIA (ARIA-E和ARIA-H) 的分类和描述.
对ARIA的诊断标准和监测指南的讨论.

主要成果:

MAB免疫疗法通过减少粉样蛋白负担为AD提供了一种新的治疗途径.
以 (ARIA-E) 或出血 (ARIA-H) 为特征的ARIA是MAB治疗的重要并发症.
ARIA是通过MRI诊断的,需要仔细监测和分类.

结论:

MABs是阿尔茨海默氏症的有希望的新疗法,但必须管理ARIA等潜在并发症.
放射科医生在识别和分类ARIA中发挥着至关重要的作用,以确保患者的安全.
了解ARIA的病原和成像特征对于将其与诸如脑粉样血管病变等疾病区分开来至关重要.

更多相关视频

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Published on: April 19, 2021

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...